Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo takes on advanced cancers

NCT ID NCT07665970

Disease control Sponsor: Sinocelltech Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether two experimental drugs, SCTB41 and SCTB39G, given together every three weeks, are safe and can shrink tumors in adults with advanced solid tumors that have not responded to standard treatments. The study will enroll 112 participants across multiple centers. It is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SCTB41 and SCTB39G (two experimental drugs given together by IV every 3 weeks)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapy.
What could go wrong
This is an early phase 1/2 trial with only 112 participants, so it is too soon to know if the combination is safe or effective. Side effects are unknown and could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 112 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Voluntarily sign the informed consent form (ICF); 2. Male or female, ≥ 18 years and ≤ 75 years old; 3. Survival duration more than 3 months; 4. ECOG score ≤ 1 point; 5. Histologically or cytologically confirmed diagnosis of advanced malignant solid tumor； 6. At least one measurable tumor lesion according to RECIST v1.1; 7. Adequate organ and bone marrow function. Exclusion Criteria: 1. Has participated in another clinical study within 4 weeks prior to the first dose; 2. Has previously received other immunotherapies other than PD-(L)1 inhibitors； 3. Other malignancies diagnosed within 5 years prior to the enrollment; 4. Participants with brainstem, meningeal, spinal metastases, or compression; active central nervous system metastases; 5. Significant bleeding risk; 6. Presence of pleural effusion, peritoneal effusion, or ascites; 7. Received chemotherapy, immunotherapy, biologic therapy, or other antitumor treatments within 4 weeks before enrollment； 8. History of permanent discontinuation of immunotherapy due to immune-related toxicity or occurrence of ≥ Grade 3 irAEs; 9. Presence of any active autoimmune disease or a history of autoimmune disease with an expected recurrence; 10. History of severe allergies, severe drug allergies (including unapproved investigational drugs); 11. History of organ transplantation or stem cell transplantation; 12. Need for immunosuppressive drugs within 2 weeks prior to enrollment or anticipated during the study; 13. Pregnant or breastfeeding female.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced malignant solid tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced malignant solid tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.